|
1）Simonneau G, Gatzoulis MA, Adatia I, et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol. 2013; 62: D34-41
|
|
|
|
2）中西宣文, 安藤太三, 植田初江, 他．肺高血圧症治療ガイドライン（2012年改訂版）．2013．http: //www.j-circ.or.jp/guideline/pdf/JCS2012_nakanishi_h.pdf
|
|
|
|
|
|
3）難病医学研究財団/難病情報センター. 肺静脈閉塞症/肺毛細血管腫症. http: //www.nanbyou.or.jp/entry/3869
|
|
|
|
|
|
4）Mandel J, Mark EJ, Hales CA. Pulmonary veno-occlusive disease. Am J Respir Crit Care Med. 2000; 162: 1964-73
|
|
|
|
|
|
5）Runo JR, Vnencak-Jones CL, Prince M, et al. Pulmonary veno-occlusive disease caused by an inherited mutation in bone morphogenetic protein receptor II. Am J Respir Crit Care Med. 2003; 167: 889-94
|
|
|
|
|
|
6）Assaad AM, Kawut SM, Arcasoy SM, et al. Platelet-derived growth factor is increased in pulmonary capillary hemangiomatosis. Chest. 2007; 131: 850-5
|
|
|
|
|
|
7）Eyries M, Montani D, Girerd B, et al. EIF2AK4 mutations cause pulmonary veno-occlusive disease, a recessive form of pulmonary hypertension. Nat Genet. 2014; 46: 65-9
|
|
|
|
|
|
8）Best DH, Sumner KL, Austin ED, et al. EIF2AK4 mutations in pulmonary capillary hemangiomatosis. Chest. 2014; 145: 231-6
|
|
|
|
|
|
9）Tenorio J, Navas P, Barrios E, et al. A founder EIF2AK4 mutation causes an aggressive form of pulmonary arterial hypertension in Iberian Gypsies. Clin Genet. 2015; 88: 579-83
|
|
|
|
|
|
10）Ranchoux B, Gunther S, Quarck R, et al. Chemotherapy-induced pulmonary hypertension: role of alkylating agents. Am J Pathol. 2015; 185: 356-71
|
|
|
|
|
|
11）Perros F, Gunther S, Ranchoux B, et al. Mitomycin-induced pulmonary veno-occlusive disease: evidence from human disease and animal models. Circulation. 2015; 132: 834-47
|
|
|
|
|
|
12）Lathen C, Zhang Y, Chow J, et al. ERG-APLNR axis controls pulmonary venule endothelial proliferation in pulmonary veno-occlusive disease. Circulation. 2014; 130: 1179-91
|
|
|
|
|
|
13）Pietra GG, Capron F, Stewart S, et al. Pathologic assessment of vasculopathies in pulmonary hypertension. J Am Coll Cardiol. 2004; 43: 25S-32S
|
|
|
|
|
|
14）Lantuejoul S, Sheppard MN, Corrin B, et al. Pulmonary veno-occlusive disease and pulmonary capillary hemangiomatosis: a clinicopathologic study of 35 cases. Am J Surg Pathol. 2006; 30: 850-7
|
|
|
|
|
|
15）Dorfmuller P, Humbert M, Perros F, et al. Fibrous remodeling of the pulmonary venous system in pulmonary arterial hypertension associated with connective tissue diseases. Hum Pathol. 2007; 38: 893-902
|
|
|
|
|
|
16）Resten A, Maitre S, Humbert M, et al. Pulmonary hypertension: CT of the chest in pulmonary venoocclusive disease. AJR Am J Roentgenol. 2004; 183: 65-70
|
|
|
|
|
|
17）Frazier AA, Franks TJ, Mohammed TL, et al. From the Archives of the AFIP: pulmonary veno-occlusive disease and pulmonary capillary hemangiomatosis. Radiographics. 2007; 27: 867-82
|
|
|
|
|
|
18）Mineo G, Attina D, Mughetti M, et al. Pulmonary veno-occlusive disease: the role of CT. Radiol Med. 2014; 119: 667-73
|
|
|
|
|
|
19）Rabiller A, Jais X, Hamid A, et al. Occult alveolar haemorrhage in pulmonary veno-occlusive disease. Eur Respir J. 2006; 27: 108-13
|
|
|
|
|
|
20）Lederer H, Muggli B, Speich R, et al. Haemosiderin-laden sputum macrophages for diagnosis in pulmonary veno-occlusive disease. PLoS One. 2014; 9: e115219
|
|
|
|
|
|
21）Montani D, Price LC, Dorfmuller P, et al. Pulmonary veno-occlusive disease. Eur Respir J. 2009; 33: 189-200
|
|
|
|
|
|
22）小川愛子．V その他の肺動脈性肺高血圧症の診療指針と実践 6. 肺静脈閉塞性疾患/肺毛細血管腫症， 肺高血圧症診療マニュアル．伊藤 浩，松原広己，編．東京: 南江堂; 2012. p.152-60
|
|
|
|
|
|
23）Laveneziana P, Montani D, Dorfmuller P, et al. Mechanisms of exertional dyspnoea in pulmonary veno-occlusive disease with EIF2AK4 mutations. Eur Respir J. 2014; 44: 1069-72
|
|
|
|
|
|
24）Galie N, Corris PA, Frost A, et al. Updated treatment algorithm of pulmonary arterial hypertension. J Am Coll Cardiol. 2013; 62: D60-72
|
|
|
|
|
|
25）Wille KM, Sharma NS, Kulkarni T, et al. Characteristics of patients with pulmonary venoocclusive disease awaiting transplantation. Ann Am Thorac Soc. 2014; 11: 1411-8
|
|
|
|
|
|
26）Ogawa A, Miyaji K, Yamadori I, et al. Safety and efficacy of epoprostenol therapy in pulmonary veno-occlusive disease and pulmonary capillary hemangiomatosis. Circ J. 2012; 76: 1729-36
|
|
|
|
|
27）Overbeek MJ, van Nieuw Amerongen GP, Boonstra A, et al. Possible role of imatinib in clinical pulmonary veno-occlusive disease. Eur Respir J. 2008; 32: 232-5
|
|
|
|
|
|
28）Adachi S, Hirashiki A, Kondo T, et al. Imatinib is partially effective for the treatment of pulmonary capillary hemangiomatosis. Intern Med. 2014; 53: 603-7
|
|
|
|
|